HEPA - Hepion Pharmaceuticals, Inc.
IEX Last Trade
0.4902
0.004 0.857%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:56:40 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$0.49
0.00
0.86%
Fundamental analysis
10%
Profitability
0%
Dept financing
10%
Liquidity
50%
Performance
10%
Performance
5 Days
2.02%
1 Month
-26.81%
3 Months
-27.23%
6 Months
-54.55%
1 Year
-84.85%
2 Year
-91.23%
Key data
Stock price
$0.49
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.51 - $3.69
52 WEEK CHANGE
-$86.08
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Robert T. Foster
Region: US
Website: hepionpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: hepionpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.
Recent news